Deucravacitinib

Specifications

1609392-27-9CAS Number

870-304-3EC Number

6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamideIUPAC Name

C20H22N8O3Chemical Formula

425.5 g/molMolecular Weight

Deucravacitinib; 1609392-27-9; BMS-986165; Sotyktu; N0A21N6RAU; RefChem:58358; Tyk2-IN-4; 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide; BMS986165; Deucravacitinib [USAN]; MFCD31715455; 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide; Deucravacitinib (BMS-986165); 6-[(Cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)-3-pyridazinecarboxamide; Tyk2-IN-4(BMS986165); bms 986165; Sotyktu (TN); UNII-N0A21N6RAU; Deucravacitinib (JAN/USAN); DEUCRAVACITINIB [INN]; DEUCRAVACITINIB [JAN]; orb1220268; orb1308545; CHEMBL4435170; DEUCRAVACITINIB [WHO-DD]; SCHEMBL20520348; SCHEMBL29424395; Deucravacitinib(BMS986165)?; GTPL10432; C20H22N8O3; DTXSID701358473; GLXC-20380; SMSSF-0676928; EX-A3154; JPC39227; BDBM50507816; NSC825520; WHO 11342; AKOS040741395; AT18623; EBC-225024; NSC-825520; compound 11 [PMID: 31318208}; NCGC00687789-01; NCGC00687789-03; (BMS-986165); 6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide; AC-31543; MS-27491; HY-117287; CS-0065044; D11817; T14687; EN300-22276121; 3-Pyridazinecarboxamide, 6-((cyclopropylcarbonyl)amino]-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)N-(methyl-d3)-; 3-Pyridazinecarboxamide, 6-[(cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)-; 4-(2-(4-(Benzyloxy)phenyl)acetamido)-1-(3'-chlorobiphenylcarbonyl)piperidine-4-carboxylic acid; 6-((cyclopropylcarbonyl)amino]-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-((2H3)methyl)pyridazine-3-carboxamide; 6-CYCLOPROPANEAMIDO-4-{[2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL]AMINO}-N-(?H?)METHYLPYRIDAZINE-3-CARBOXAMIDE; Deucravacitinib; 3-Pyridazinecarboxamide, 6-[(cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)-; 6-[(Cyclopropylcarbonyl)amino]-4-[[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino]-N-(methyl-d3)-3-pyridazinecaSynonyms

Products Containing Deucravacitinib

소틱투정6밀리그램(듀크라바시티닙)SOTYKTU 6 MG COMPRIMIDOS RECUBIERTOS CON PELICULA SOTYKTU 6 mg, comprimé pelliculé DeucravacitinibBMS-986165，Deucravacitinib Deucravacitinib Deucravacitinib Deucravacitinib Deucravacitinib BMS-986165

Companies Selling Deucravacitinib

Shanghai Lizhuo Pharmaceutical Technology Co.,Ltd.China

Hangzhou Royall Import & Export Co.,LtdChina

Jiangsu Magic Biotechnology Co., LtdChina

Wuxi Hexia Chemical CompanyChina

CHANGZHOU PHARMACEUTICAL FACTORYChina

Bristol-Myers Squibb Pharma EeigSpain

BRISTOL-MYERS SQUIBB PHARMAIreland

(유

(유)한국비엠에스제약Republic of Korea

BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.China

Shanghai Rochi Pharmaceutical Co.,Ltd.China